Ibuprofen/Magnesium Aluminometasilicate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ibuprofen/Magnesium Aluminometasilicate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ibuprofen/Magnesium Aluminometasilicate can convert its Small molecule drug profile and CAIX x COX-1 x COX-2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ibuprofen/Magnesium Aluminometasilicate (query alias: Ibuprofen/Magnesium Aluminometasilicate) |
|---|---|
| Modality / target | Small molecule drug; CAIX x COX-1 x COX-2; CAIX inhibitors, COX-1 inhibitors, COX-2 inhibitors |
| Highest global status | Approved |
| Originator | GC Biopharma Corp. |
| Active developers | GC Biopharma Corp. |
The MCP disease footprint includes Fever, Pain. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07682558 | Phase 3 | Not yet recruiting | 318 | Change in cancer pain |
| ChiCTR2600127792 | Phase 2/3 | Not yet recruiting | 59 | Difference in the temperature-time curve within 4 hours after the first administration. |
| CTR20262748 | Not Applicable | 进行中 （尚未招募） | 30 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efficacy of Pain Control Following Root Canal Treatment Using Paracetamol Alone and in Combination With Three Different Non-Steroidal Anti-Inflammatory Analgesics
Phase 2; n=185; evaluation: not stated. Reported fields: -; -; before treatment(Median) = 8 score on a scale (Full Range, 0 - 10)
A Phase 3b, Randomized, Open-Label Study of HTX-011 as the Foundation of a Non-opioid, Multimodal Analgesic Regimen to Decrease Opioid Use Following Unilateral Open Inguinal Herniorrhaphy
Phase 3; n=209; evaluation: not stated. Reported fields: Proportion of Subjects Who do Not Receive an Opioid Prescription Through the Day 15 Visit = 97 Participants ; -; Proportion of Subjects Who do Not Receive an Opioid Prescription Through the Day 15 Visit = 95 Participants
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
Phase 4; n=86; evaluation: not stated. Reported fields: Day 1 Post-Operatively(Mean) = 4.4 score on a scale (Standard Deviation, 0.2); -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ibuprofen/Magnesium Aluminometasilicate addresses Fever, Pain. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals | Approved | Financial terms not disclosed |
| 2025-12-17 | EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort® | Approved | Financial terms not disclosed |
| 2022-12-20 | Perrigo to collaborate with Avecho Biotechnology in the development of TPM-enhanced ibuprofen gel for pain management in the US. | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
